Extended Data Fig. 3: HER3-DXd interactions with tumor cells.
From: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
(a, b) Pie chart showing the proportion of the different cell phenotypes among the HER3-DXd-positive cells at C1D3 in responders (a) and non-responders (b); (c) Dynamics of HER3-positive cells after 1 or 2 doses of HER3-DXd in responders and non-responders (n = 39), showing a greater reduction on-treatment of HER3-positive cells in responders as compared to non-responders (Mann-Whitney U test, p-value 0.011).
